R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018)

Article  PubMed  Google Scholar 

T.K. Choueiri, R.J. Motzer, Systemic Therapy for metastatic renal-cell carcinoma. N. Engl. J. Med. 376(4), 354–366 (2017)

Article  CAS  PubMed  Google Scholar 

T. Klatte et al., Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev. Urol. 9(2), 47–56 (2007)

PubMed  PubMed Central  Google Scholar 

B.I. Rini, S.C. Campbell, B. Escudier, Renal cell carcinoma. Lancet 373(9669), 1119–1132 (2009)

Article  CAS  PubMed  Google Scholar 

K. Yamazaki et al., Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 22(6), 847–852 (2003)

Article  CAS  PubMed  Google Scholar 

E. Jonasch, J. Gao, W.K. Rathmell, Renal cell carcinoma. BMJ 349, g4797 (2014)

Article  PubMed  PubMed Central  Google Scholar 

H. Moch et al., The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur. Urol. 82(5), 458–468 (2022)

Article  PubMed  Google Scholar 

C.A. Grandinetti, B.R. Goldspiel, Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 27(8), 1125–1144 (2007)

Article  CAS  PubMed  Google Scholar 

Y. Adachi et al., Inhibition of FGFR reactivates IFNgamma signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies. Cancer Res 82(2), 292–306 (2022)

Article  CAS  PubMed  Google Scholar 

Cancer Genome Atlas Research Network, Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 499(7456), 43–49 (2013). https://doi.org/10.1038/nature12222

Article  CAS  Google Scholar 

G. Hudes et al., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271–2281 (2007)

Article  CAS  PubMed  Google Scholar 

X. Sheng et al., Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: a three-arm, randomised, double-blind, multicentre phase III study (CONCEPT). Eur. J. Cancer 178, 205–215 (2023)

Article  CAS  PubMed  Google Scholar 

J.A. Garcia, B.I. Rini, Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. 57(2), 112–125 (2007)

Article  PubMed  Google Scholar 

G. Fyfe et al., Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688–696 (1995)

Article  CAS  PubMed  Google Scholar 

J.C. Yang et al., Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21(16), 3127–3132 (2003)

Article  CAS  PubMed  Google Scholar 

D.F. McDermott et al., Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23(1), 133–141 (2005)

Article  CAS  PubMed  Google Scholar 

S. Pyrhonen et al., Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 17(9), 2859–2867 (1999)

Article  CAS  PubMed  Google Scholar 

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353(9146), 14–7 (1999)

J. Folkman, Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6 Suppl 16), 15–18 (2002)

Article  CAS  PubMed  Google Scholar 

E.D. Deeks, G.M. Keating, Sunitinib. Drugs 66(17), 2255–66 (2006). (discussion 2267-8)

Article  CAS  PubMed  Google Scholar 

G.S. Papaetis, K.N. Syrigos, Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 23(6), 377–389 (2009)

Article  CAS  PubMed  Google Scholar 

D. Romero, Belzutifan has potential in RCC. Nat. Rev. Clin. Oncol. 18(6), 322 (2021)

Article  CAS  PubMed  Google Scholar 

L.R. Medina et al., Update on the treatment of metastatic renal cell carcinoma. World J. Clin. Oncol. 13(1), 1–8 (2022)

Article  Google Scholar 

N. Gavrielatou et al., Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat. Rev. 84, 101977 (2020)

Article  CAS  PubMed  Google Scholar 

D.M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252–264 (2012)

Article  CAS  PubMed  PubMed Central  Google Scholar 

A.E. Kam, A. Masood, R.T. Shroff, Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol. Hepatol. 6(11), 956–969 (2021)

Article  PubMed  Google Scholar 

What are single nucleotide polymorphisms (SNPs)? (2022–3–22)[2022–12–21] (2022)

A.E. Koch et al., Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258(5089), 1798–1801 (1992)

Article  CAS  PubMed  Google Scholar 

D. Huang et al., Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70(3), 1063–1071 (2010)

Article  CAS  PubMed  PubMed Central  Google Scholar 

D. Hacking et al., Increased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility. Genes Immun. 5(4), 274–282 (2004)

Article  CAS  PubMed  Google Scholar 

A. Yuan et al., The role of interleukin-8 in cancer cells and microenvironment interaction. Front. Biosci. 10, 853–865 (2005)

Article  CAS  PubMed  Google Scholar 

B.I. Rini et al., Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). J. Clin. Oncol. 28(15_suppl), 4501–4501 (2010)

C.F. Xu et al., IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. Br J Cancer 112(7), 1190–1198 (2015)

Article  CAS  PubMed  PubMed Central  Google Scholar 

P.C. Brooks, R.A. Clark, D.A. Cheresh, Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264(5158), 569–571 (1994)

Article  CAS  PubMed  Google Scholar 

J.S. Desgrosellier, D.A. Cheresh, Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10(1), 9–22 (2010)

Article  CAS  PubMed  PubMed Central  Google Scholar 

D.J. Crona et al., Genetic variants of VEGFA and FLT4 are determinants of survival in renal cell carcinoma patients treated with sorafenib. Cancer Res. 79(1), 231–241 (2019)

Article  CAS  PubMed  Google Scholar 

M.S. Del, Z. Salah, R.I. Aqeilan, WWOX: its genomics, partners, and functions. J. Cell. Biochem. 108(4), 737–745 (2009)

Article  Google Scholar 

A. Kaipainen et al., Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. U. S. A. 92(8), 3566–3570 (1995)

Article  CAS  PubMed  PubMed Central  Google Scholar 

N.R. Smith et al., Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin. Cancer Res. 16(14), 3548–3561 (2010)

Article  CAS  PubMed  Google Scholar 

N. Ferrara, VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2(10), 795–803 (2002)

Article  CAS  PubMed  Google Scholar 

H. Gerhardt et al., VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161(6), 1163–1177 (2003)

Article  CAS  PubMed  PubMed Central  Google Scholar 

T. Veikkola et al., Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60(2), 203–212 (2000)